A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

Summary

This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in patients with advanced or metastatic solid tumors who are not candidates for approved or available therapies.

Timeline

Start

2021-09-16

Primary completion

2025-02-26

Completion

2025-03-24

Outcome

Outcome not reported

Stopped (Business): “After careful review of Taiho's ongoing portfolio and data obtained so far in the context of broader landscape of clinical development in NSCLC HER2mut, Sponsor has made a strategic decision to terminate this study and not based on safety concerns.”

Drugs

Indications